ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prednisone and treatment"

  • Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting

    Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)

    Soledad Retamozo1, Maria Jezabel Haye Salinas2, Juan Pablo Pirola3, Diego Baenas2, Ana C. Alvarez4, Veronica Saurit3, Alejandro Alvarellos5, Christian A. Waimann6, Gustavo Citera7,8, Fernando Dal Pra9, Celeste Orozco9, Federico Ceccato10, Sergio Paira10, MV Martire11, G Crespo Amaya11, Anastasia Secco11, M Mamani11, Javier Rosa12, Enrique Soriano12, Josefina Marcos13, Mercedes Argentina García14, Carolina Costi15, María M Zalazar16, Alejandro Martinez Muñoz16, Oscar Luis Rillo17, Horacio Berman18, Alberto Berman18, Francisco Colombres18, Edson Javier Velozo19, Vicente Ricardo Juarez20, M Crespo20, A Quinteros21, M Leal21, G Salvatierra22, Monica Sacnún23, R Quintana23, M Abdala24 and Francisco Caeiro25, 1Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, 2Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 3Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 4Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, 5Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 6Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, 7Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, 8Rheumatology, CONAART - IREP, Buenos Aires, Argentina, 9Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, 10Hospital Dr José María Cullen, Santa Fe, Argentina, 11Hospital Bernardino Rivadavia, CABA, Argentina, 12Hospital Italiano De Buenos Aires, CABA, Argentina, 13Hospital San Martin, La Plata, Argentina, 14Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 15Hospital San Martín, LaPlata, Argentina, 16Hospital Pirovano, CABA, Argentina, 17Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, 18Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, 19Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, 20Hospital Señor Del Milagro, Salta, Argentina, 21Centro Integral De Reumatología, Tucumán, Argentina, 22Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, 23Hospital Provincial De Rosario, Rosario, Argentina, 24Hospital Provincial Del Centenario, Rosario, Argentina, 25Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina

    Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
  • Abstract Number: 2026 • 2013 ACR/ARHP Annual Meeting

    Initial Dose Of Prednisolone For Japanese Patients With Polymyalgia Rheumatica

    Akiko Aoki1, Hiroshi Oka2 and Mitsuyuki Nakamura3, 1General Medicien, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, 2Rheumatic Disease Center, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, 3Rheumatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan

    Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory condition of elderly persons. Clinical symptoms respond to low-dose glucocorticoids, but treatment is often required for several…
  • Abstract Number: 2357 • 2012 ACR/ARHP Annual Meeting

    Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients

    Marco A. Alba1, Ana García-Martínez2, Itziar Tavera-Bahillo1, Sergio Prieto-González1, Montserrat Butjosa3, Georgina Espígol4, Marc Corbera4, Ester Planas4, Jose Hernandez-Rodriguez5 and Maria C. Cid6, 1Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Department of Emergency Medicine, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clinic University Barcelona, Barcelona, Spain, 4Systemic Autoimmune Diseases, Vasculitis research unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 5Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 6Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Background/Purpose: In spite of the satisfactory initial response to glucocorticoid treatment, patients with giant cell arteritis (GCA) frequently experience relapses during follow-up. The objectives of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology